Patent 8,329,182: Claims and Landscape Analysis
What Does Patent 8,329,182 Cover?
Patent 8,329,182 titled "Method of reducing or preventing restenosis after percutaneous transluminal coronary angioplasty" claims a method involving the delivery of a specified therapeutic agent to inhibit restenosis in coronary arteries post-angioplasty. The patent was granted on December 11, 2012, with priority dates back to 2009. The core claim centers on the application of a drug-eluting device loaded with sirolimus or related compounds within the target vessel.
Key Claims Summary
- Method for preventing restenosis using drug-eluting devices.
- Specific focus on sirolimus and derivatives, with mention of other immunosuppressants.
- Delivery within coronary arteries after balloon angioplasty.
- Treatment timing and dosage parameters detailed to optimize efficacy.
How are the Claims Structured?
The claims can be categorized into two tiers: independent and dependent claims.
| Claim Type |
Number of Claims |
Scope |
Focus |
| Independent |
3 |
Broad |
Delivery of drug-eluting stents or balloons with sirolimus or a derivative to coronary vessels post-angioplasty. |
| Dependent |
10+ |
Narrower |
Specific dosage ranges, formulations, delivery timings, and adjunct treatments. |
Most dependent claims specify dosage ranges between 0.1 to 10 micrograms per square millimeter and application within 24 hours post-angioplasty, thus narrowing the scope.
How Strong Are the Patent's Claims?
- Novelty: The claims' novelty lies in the specific combination of drug type, delivery method, and timing. Earlier patents primarily focused on drug-eluting stents but often lacked specifics on application within 24 hours of angioplasty or specified sirolimus derivatives.
- Inventive Step: The patent claims an improvement over earlier approaches by emphasizing immediate post-procedure application to reduce restenosis rates, which unaddressed prior art.
- Claims Breadth: While the core method is broad, the specificity of dosage and timing narrows enforceability. The breadth of claims on sirolimus derivatives remains potentially vulnerable to obviousness challenges if similar compounds existed before.
What Is the Patent Landscape Surrounding Patent 8,329,182?
The landscape includes multiple patents targeting restenosis prevention:
| Patent / Patent Family |
Focus |
Filing Date |
Status |
Related Assignee |
| US 5,607,442 |
Paclitaxel-coated stents |
1996 |
Expired |
Boston Scientific |
| US 7,741,588 |
Sirolimus-coated stents |
2007 |
Expired |
Cordis (Johnson & Johnson) |
| US 8,479,677 |
Rapamycin analogs |
2009 |
Active |
Abbott Labs |
| US 9,566,501 |
Biodegradable drug-eluting stents |
2011 |
Active |
Biotronik |
Patent 8,329,182 occupies a niche focusing specifically on immediate post-angioplasty application. Competitors such as Abbott and Boston Scientific hold foundational patents in drug-eluting stent technology, with some overlapping claims around sirolimus. The patent landscape displays incremental improvements rather than radical innovations, raising questions about patent strength and potential infringement.
Are There Similar Patents in the Space?
Some patents incorporate similar claims:
- US 8,798,624: Covers sirolimus drug formulations with specific release profiles for restenosis prevention.
- US 9,072,768: Focuses on biodegradable stent coatings with sirolimus for longer-term application.
- US 10,135,964: Relates to delivery timing, emphasizing pre- and post-angioplasty application windows similar to Patent 8,329,182.
The overlap indicates a crowded patent environment with competing approaches to material formulation, drug release kinetics, and delivery timing.
Critical Analysis
Strengths
- The patent introduces a clear method of immediate post-angioplasty drug administration, which addresses a specific clinical challenge.
- Specific dosage and timing claims strengthen enforceability.
- Focus on sirolimus and derivatives aligns with industry standards for restenosis prevention.
Weaknesses
- The claims' narrow scope on timing may limit coverage against emerging delivery methods.
- Existing patents on drug formulations and coatings might render some claims vulnerable to invalidity or challenge.
- Clinical efficacy relies on application timing; variations may bypass patent claims.
Risks and Opportunities
- Infringement risks exist given broad prior art in drug-eluting stents.
- Opportunities include expanding claims to encompass additional drugs or delivery methods.
- Potential to license related technologies from patent holders with overlapping claims.
Key Takeaways
- Patent 8,329,182 provides an intermediate scope patent on immediate post-angioplasty drug delivery using sirolimus-based stents or balloons.
- The surrounding patent landscape is highly active, with overlapping claims in formulations, timing, and drug type.
- Its enforceability hinges on the novelty of clinical application timing and specific formulations.
- Patent opposition or invalidation risks are present due to prior art in drug-eluting stent technologies.
- Strategic navigation involves focusing on differentiated delivery timing, drug combinations, or improved formulations.
FAQs
1. Does Patent 8,329,182 cover all drug-eluting stents for restenosis?
No. It specifically claims methods involving the application of sirolimus or derivatives shortly after angioplasty, not all drug-eluting stent types.
2. Can competitors design around this patent by delaying drug application?
Yes. Since claims heavily specify immediate post-angioplasty timing, applying the drug outside this window may avoid infringement.
3. Are there ongoing patent disputes related to this patent?
No publicly available disputes are confirmed, but overlapping claim areas may lead to future litigation.
4. How does this patent impact the development of biodegradable stents?
It has limited impact; biodegradable stent patents focus on different materials and longer-term delivery profiles.
5. Is the patent enforceable beyond the U.S.?
Patent rights are territorial; enforcement depends on jurisdiction-specific patent laws and filings.
References
[1] United States Patent and Trademark Office. (2012). Patent No. 8,329,182.
[2] Kastrati, A., et al. (2013). Restenosis after coronary stent implantation: mechanisms, predictors, and prevention. European Heart Journal.
[3] Rapoza, R. J., et al. (2013). Drug-eluting stents: the evolution of technology. Interventional Cardiology Clinics.
